Literature DB >> 6543037

Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.

J Aznar, A Estellés, V Vila, E Regañón, F España, P Villa.   

Abstract

A family with "in vitro" increased red-cell fall out from the blood clot was studied. One member of the family (JVM) had a clinical history of hemorrhages after minor trauma or dental extractions. Routine coagulation and platelet function were normal except for the fibrinogen level which was slightly low in several members. The antigenic as well as functional evaluation of factor XIII was within normal limits. No factor XIII inhibitors were present. An increase in the clot permeability index was observed in most family members. The study of the fibrinolytic system showed an enhanced lysis of euglobulins, a normal plasminogen value, normal level of fibrin/ogen degradation products, normal fibrinolytic inhibitors, and an increase in the activity of the plasminogen activator. The activity of this activator was inhibited by an antiserum against tissue-type plasminogen activator. The t-pA inhibitor was in the normal range. It is concluded that the family studied in this paper shows familial alteration in the fibrinolytic system due to an excess of plasminogen activator immunologically related to that in human tissue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6543037

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 2.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

3.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

Authors:  J Aznar; A Estellés; G Tormo; P Sapena; V Tormo; S Blanch; F España
Journal:  Br Heart J       Date:  1988-05

4.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; D L Higgins; E Pillemer; L J Levitt
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 5.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.